• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

A-431 nuclear extract (EGF treated)

Activ Motif logo

A-431-nuclear-extract-EGF-treated-AM36003

Synonyms

A-431, A431, EGF, treated, stimulated, nuclear extract, nuclear, extract, A-431 nuclear extract, nuclear, extract, 431, nuclear extract, nuclear, extract, lysate, nuclear lysate, A431 nuclear extract, A-431 cell extract, A-431 cell nuclear extract, A431 nuclear cell extract, human epidermoid carcinoma, epidermoid carcinoma, EGFR, epidermal growth factor receptor, EGF, epidermal growth factor, EGFR positive control, EGFR signalling cascade, EGFR signaling cascade, EGF signalling cascade, EGF signaling cascade, EGFR signalling, EGF signalling, EGFR signaling, EGF signaling, cell cycle, cell growth, cancer signalling pathways, cancer, p53, cancer signaling pathway, cell division, cancer-associated pathways, protein,protein interaction, protein,protein binding, protein protein interaction, protein protein binding, protein-protein interaction, protein-protein binding,protein,DNA binding, prot

Name Format Cat No. Price

Contents

200 µg of A-431 nuclear extract (EGF treated) at 2.5 µg/µl.

Background

A-431 nuclear extract (EGF treated) was prepared from cell cultures of the human epidermoid carcinoma A431 cell line. These cells are characterized by abnormally high levels of expression of epidermal growth factor receptor (EGFR), approximately 3 x 106/cell, on the cell surface and exhibits a biphasic response to varying concentrations of epidermal growth factor (EGF). Specifically, lower (pmol) concentrations of EGF stimulates cell growth while higher (nmol) concentrations inhibits cell growth and induces terminal differentiation. Therefore, these cells are commonly used as a positive control for EGFR expression and in studies of EGFR downstream signaling cascades. These cells are also highly responsive to mitogenic stimuli and are naturally devoid of p53, so are frequently used in cancer and cell cycle-associated studies.

Application Notes

A-431 nuclear extract (EGF treated) is specifically recommended for analysis of 1) EGFR expression and downstream signaling cascades, 2) cell cycle, and 3) cancer-associated signaling pathways.

Extract Origin

Human Epidermoid Carcinoma

Extract Composition

A-431 nuclear extract (EGF treated) is supplied in Dilution Buffer (20 mM Hepes (pH 7.9), 100 mM KCl, 1 mM MgCl2, 20% glycerol, 0.5 mM PMSF and 0.5 mM DTT). Cells were cultured in medium supplemented with 10 ng/ml EGF (epidermal growth factor) for 10 minutes at 37°C immediately prior to harvesting.

Quality Control

Extracts have been quality control tested by Western blot.